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Background/aim: Various studies have shown that adult patients with polycystic ovary syndrome (PCOS) have higher levels of anxiety
and depression compared to their normal counterparts. However, it is still unclear whether these mood disorders already exist in
adolescents affected by PCOS. The aim of the present study is to assess differences in anxiety and depression levels between adolescents
with PCOS and age- and body mass index (BMI)-matched controls and to determine the possible factor(s) impacting these psychological
parameters in adolescents with PCOS.
Materials and methods: The study included 80 adolescents with PCOS and 50 age- and BMI-matched controls. All participants
completed standardized questionnaires assessing anxiety and depression. A multiple linear regression model was used to analyze the
impact of potential variables on anxiety and depression scores of the adolescents with PCOS.
Results: Significantly higher levels of anxiety, specifically generalized and social anxieties, as well as depression were found in adolescents
with PCOS compared to controls. Higher BMI was found to be associated with higher levels of depression and generalized anxiety, and
higher modified Ferriman–Gallwey score with higher level of panic disorder in adolescents affected by PCOS.
Conclusion: Adolescents with PCOS experience significantly more emotional distress compared to adolescents without PCOS. This
emotional distress may be related, at least in part, to certain clinical features of PCOS including obesity and hirsutism. PCOS in
adolescents should be assessed not only for the gynecological and metabolic aspects but also for the emotional aspects of the disease.
Key words: Anxiety, depression, polycystic ovary syndrome, adolescents

1. Introduction
Polycystic ovary syndrome (PCOS) is a common
endocrine disorder that occurs in 6%–10% of women
of reproductive age with a higher prevalence in obese
women (1). PCOS often presents during adolescence
and is characterized primarily by ovulatory dysfunction
and hyperandrogenism (2). The manifestations typically
associated with PCOS, including hirsutism (excess facial
and body hair), obesity, acne, and irregular menstrual
cycles, can cause considerable concern and distress with
regard to body image and feminine identity, which can
impair the psychological well-being of adolescents with
PCOS.
Numerous adult studies have revealed a higher
prevalence of psychiatric disorders, notably increased
depression, anxiety, and social phobia, in women with
PCOS (3–6). Eating disorders and suicidal behavior
* Correspondence: hcemeksiz@gmail.com

are also more common among women with PCOS (7).
Furthermore, recent studies reported that comorbid
psychiatric disorders challenge the quality of life of PCOS
patients (8). While such psychological consequences of
PCOS have been extensively documented, the underlying
factors that may predispose women with PCOS to an
increased risk of psychiatric disorders still remains unclear.
Certain features of PCOS, such as obesity, hirsutism,
infertility, and neuroendocrine dysfunction, have been
suggested as causal factors, but research findings are not
consistent (9).
Mood disorders associated with PCOS are well
established in the adult population; however, it is not well
known whether these emotional disturbances are already
present in adolescents with PCOS. Adolescence may have a
negative impact on the symptomatology of young patients
with PCOS. It represents a period where the concerns about
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physical appearance are most distinct (10). Body image and
related self-concept arise as important factors associated
with health and well-being during this life stage (11).
Any deviation from the ideal body figure can easily result
in depressive symptomatology, anxiety, and lower selfesteem, contributing significantly to the higher overall rate
of psychiatric disorders among adolescents. Given that the
physical manifestations of PCOS start to become evident
at younger ages, likely owing to the current childhood
obesity epidemic worldwide, and that the sensitivity of
girls to their body image is more prevalent during the teen
years, evaluating mood disorders among adolescents with
PCOS becomes notably pertinent. However, little attention
has been paid so far to the psychosocial implications of
PCOS in adolescents. Therefore, the aim of the present
study was to assess anxiety and depression levels of
adolescents with PCOS in comparison to age- and body
mass index (BMI)-matched controls and to determine the
possible factor(s) affecting these psychological parameters
in adolescents affected by the syndrome.
2. Materials and methods
2.1. Subjects
This cross-sectional study was performed during the period
from May 2013 to July 2014 and included 80 adolescent
girls with the diagnosis of PCOS (17.23 ± 1.15 years, range:
16–19 years) who were recruited from the Outpatient
Obstetrics and Gynecology Clinic and Outpatient Pediatric
Clinic of Namık Kemal University Hospital in Tekirdağ
and the Outpatient Pediatric Endocrinology Clinic of Gazi
University Hospital in Ankara. An equal number of patients
and controls from both centers participated in the study.
All the patients were at least 3 years postmenarcheal and
met the 2003 Rotterdam diagnostic criteria for PCOS (12).
They had clinical and/or biochemical hyperandrogenism,
chronic oligo- and/or anovulation, and/or polycystic
ovaries on ultrasound. Nonclassic congenital adrenal
hyperplasia, hyperprolactinemia, Cushing’s syndrome,
thyroid dysfunction, androgen-secreting tumors, language
or cognitive difficulties preventing reliable completion of
the questionnaire, and presence of any other coexisting
acute or chronic illness unrelated to PCOS that may affect
psychological test scores were the exclusion criteria of the
study. A total of 50 age- and BMI-matched adolescent
girls (17.00 ± 0.99 years, range: 16–19 years) from the
general population, who had regular menses and were
normoandrogenic, served as controls. The participants
were not taking any medication for at least 3 months before
the study. The study protocol was approved by the Clinical
Trial Ethics Committee of the two centers. Informed
consent and assent were obtained from all subjects and
their parents.
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2.2. Measurements
2.2.1. Clinical and laboratory measures
All the adolescent girls participating in this study
were single high school students attending public
schools and having health insurance. They were
subjected to physical examination and laboratory tests.
Anthropometric measurements including BMI, waist
and hip circumferences, and waist-to-hip ratio were
determined. Androgen levels [total testosterone and
dehydroepiandrosterone sulfate (DHEAS)] and clinical
evidence of androgen excess [modified Ferriman–Gallwey
(mFG) score] were measured. Hirsutism was defined by
a mFG score of >7. Other laboratory tests were fasting
glucose, insulin, total cholesterol, high-density lipoprotein
cholesterol,
triglycerides,
17-hydroxyprogesterone,
follicle-stimulating hormone, luteinizing hormone,
estradiol, and 2-h plasma glucose after a standard 75-g
oral glucose tolerance test. Homeostatic model assessment
of insulin resistance (HOMA-IR) was also calculated for
each participant according to the formula [fasting glucose
(mg/L) × fasting insulin (mU/mL)]/405. All sampling
procedures were performed between 0800 and 1000 hours
after an overnight fast.
2.2.2. Psychological measures
All participants completed the Screen for Child Anxiety
Related Emotional Disorders (SCARED) and the Child
Depression Inventory (CDI).
2.2.2.1. Screen for Child Anxiety Related Emotional
Disorders
SCARED is a 41-item self-report measure designed to
screen for DSM-IV anxiety disorders. Birmaher et al.
(13) developed the scale and it was adapted to Turkish by
Çakmakçı (14). It includes 5 factors: somatic/panic (13
items), generalized anxiety (9 items), separation anxiety
(8 items), social phobia (7 items), and school phobia (4
items). The participants rated the items of each factor
on a 3-point scale (0 = not true or hardly ever true, 1 =
sometimes true, and 2 = true or often true). The SCARED
total score, derived by adding the score of the 41 items,
ranges from 0 to 82. Higher total scores indicate a higher
level of anxiety.
2.2.2.2. Child Depression Inventory
The CDI is a self-assessment scale for children aged between
6 and 17 years that is used in investigating childhood
depression. Kovacs (15) developed the inventory based
on the Beck Depression Inventory and it was adapted to
Turkish by Öy (16). The CDI consists of 27 self-report
items and each item of the scale contains 3 sentences,
which are scored as 0, 1, or 2, depending on the severity
of the symptom. Higher scores (max = 54) represent more
severe depression.
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2.3. Statistical analysis
After entering the data using SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA), analysis of the results was performed
using percentage distribution for qualitative data and
median (25th and 75th) or mean (standard deviation) for
quantitative data. The statistical tests used were the Shapiro–
Wilk test for normality, the chi-square test for qualitative
data comparison of groups, and the independent samples
t-test and Mann-Whitney U test for quantitative data
comparison of groups, as appropriate. A multiple linear
regression model was used to determine the relationship
between the independent variables including BMI score,
mFG score, age, paternal education, maternal education,
and family income and dependent variables including
SCARED and CDI scores of the adolescents with PCOS. P
< 0.05 was considered statistically significant.

3. Results
In total, 80 PCOS patients and 50 controls participated
in the study and completed the required questionnaires.
Clinical and biochemical characteristics of patients with
PCOS and controls are displayed in Table 1. Age, BMI,
parental education levels, and family income did not differ
significantly between the groups (P > 0.05). The mFG
score, total testosterone, DHEAS, and HOMA-IR values
were higher for the patient group.
The SCARED total score was higher in the PCOS
group compared to the control group (P = 0.030, Table
2). Among the subscales of SCARED, the PCOS group
had higher scores than the control group for generalized
anxiety disorder and social anxiety disorder (P = 0.042, P
= 0.035, respectively). There was no significant difference
between the groups for the remaining subscale scores of

Table 1. Clinical and biochemical characteristics of patients with PCOS and controls.

Age (years)
Body mass index (kg/m2)
Waist-hip ratio
mFG score
Total testosterone (ng/dL)
DHEAS (µg/dL)
Luteinizing hormone (U/L)
Follicle-stimulating hormone (U/L)
Estradiol (pmol/L)
FPG (mg/dL)
Two-hour plasma glucose (mg/dL)
Total cholesterol (mg/dL)
HDL-C (mg/dL)
Triglycerides (mg/dL)
Fasting insulin (µIU/mL)
HOMA-IR
Mother’s education level (%)
Elementary
High school
University
Father’s education level (%)
Elementary
High school
University
Family income (%)
<300 €
300–1000 €
>1000 €

PCOS
n = 80

Controls
n = 50

P-value

17.3 ± 1.15
24.7 (21.0–29.6)
0.85 (0.80–0.91)
14 (12–16)
42.5 (31.6–53.4)
250.6 (170.0–329.0)
5.2 (3.9–7.9)
5.1 (4.0–6.3)
38.0 (29.3–48.9)
87.0 (83.9–93.7)
98.0 (84.0–116.0)
159.8 (141.2–183.5)
47.6 (42.0–53.8)
87.1 (64.2–107.9)
11.2 (7.0–14.9)
2.3 (1.4–3.4)

17.0 ± 0.99
24.3 (20.1–27.3)
0.82 (0.77–0.90)
5 (4–6)
29.6 (23.8–45.0)
202 (144.5–261.5)
4.0 (2.6–7.9)
5.0 (3.9–6.9)
39.1 (28.7–54.1)
85.5 (82.0–90.3)
89.5 (79.7–100.0)
153.0 (136.0–165.0)
46.5 (41.8–55.1)
78.0 (63.0–104.0)
7.0 (5.1–11.8)
1.6 (1.0–2.4)

0.22
0.10
0.07
<0.001
0.001
0.009
0.007
0.540
0.860
0.07
0.005
0.06
0.90
0.35
0.007
0.008

20
59
21

24
54
22

0.83

11
58
31

16
54
30

0.74

21
49
30

26
48
26

0.79

mFG score: modified Ferriman–Gallwey score, DHEAS: dehydroepiandrosterone sulfate, FPG: fasting plasma glucose,
HOMA-IR: homeostatic model assessment of insulin resistance.
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Table 2. Comparison of SCARED and CDI scores between PCOS and control groups.
Scales

PCOS
n=80

Controls
n = 50

P-value

SCARED total
Panic disorder
Generalized anxiety disorder
Separation anxiety disorder
Social anxiety disorder
Significant school avoidance
CDI

24 (19.0–31)
6 (4–7)
6 (5–9)
4 (3–5)
7 (4–8)
1.5 (1–3)
19 (13–22)

21 (16–26)
5.5 (4–7)
5 (4–7)
4 (3–5)
5.5 (4–7)
1 (0–2)
16 (12–20)

0.030
0.337
0.042
0.152
0.035
0.054
0.047

SCARED: Screen for Child Anxiety Related Emotional Disorders, CDI: Child Depression Inventory.

panic disorder, separation anxiety disorder, and significant
school avoidance (P > 0.05 for all). Regarding CDI scores,
the PCOS group displayed a higher level of depression in
comparison to the control group (P = 0.047, Table 2).
Multiple linear regression analysis was performed
using SCARED and CDI scores of patients as dependent
variables and BMI, mFG score, age, paternal education,
maternal education, and family income as independent
variables. BMI remained independently associated with
depression (β-coefficient = 0.240, P = 0.04) and generalized
anxiety (β-coefficient = 0.263, P = 0.018), and mFG score
with panic disorder (β-coefficient = 0.310, P = 0.006).
4. Discussion
Abundant evidence from adult studies showed that women
with PCOS face significantly higher rates of anxiety and
depression (3–5). However, it is not clear whether such an
escalation already exists in adolescents with PCOS. In this
regard, the present study demonstrated that adolescent
girls who suffer from PCOS experience greater anxiety,
specifically generalized and social anxieties, as well as
greater depression compared to age- and BMI-matched
controls. In addition, analysis of all items with the multiple
linear regression model revealed that higher BMI was
associated with higher levels of depression and generalized
anxiety, and higher mFG score with a higher level of panic
disorder in adolescent girls with PCOS. This parallel rise
implies a potential relationship of depression and some
types of anxiety disorders with certain clinical features of
PCOS including obesity and hirsutism.
Several studies from different regions of the world
showed that women with PCOS are at an increased risk of
mood disorders compared to women without PCOS (5).
In a recent comprehensive metaanalysis, women affected
by PCOS were reported to have about 4 times the odds
of depressive symptoms and about 6 times the odds of
anxiety symptoms than controls, confirming the potential
detrimental effect of PCOS by itself on the psychological
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well-being of women with the condition (6). However,
most of the studies assessing psychiatric comorbidities
of PCOS were conducted in adult populations and only
a few studies involving small numbers of PCOS patients
have so far assessed the psychological consequences of the
syndrome in adolescent girls, with controversial results
(17–19). In a quantitative study, Guidi et al. evaluated the
psychological aspects of PCOS in girls aged 16–19 years
and found that adolescents with PCOS have higher levels
of psychological distress and impaired well-being and
quality of life compared to their normal counterparts (18).
In line with the results of that study, we found significantly
higher levels of depression, social anxiety, and generalized
anxiety disorders in adolescents with PCOS. Conversely, a
study conducted by Ghazeeri et al. failed to demonstrate
any relationship of PCOS with anxiety, depression, and
psychiatric symptoms in adolescent girls (19). However,
small sample size and absence of anthropometric and
clinical assessments of participants in that study might
have compromised its conclusions.
Typical clinical features of PCOS (e.g., hirsutism) or
its comorbidities (e.g., obesity) have been perceived as
stigmatizing and a cause of distress by many women with
PCOS (4). However, it still remains unclear whether PCOS
by itself or the related physical symptoms are the major
contributors to the distressing symptoms in women with
the condition (20). Previous metaanalyses investigated the
impact of BMI and hirsutism on anxiety and depression
and suggested that these symptoms have a small or
moderate effect on anxiety and depression in women with
PCOS (4,6,21). However, the contribution of these clinical
symptoms to mood may be more distinct in adolescent
girls affected by PCOS. Adolescents are more likely to be
dissatisfied with their body and consequently to experience
psychiatric problems related with their appearance or
size. In this study, the results of multiple linear regression
analysis for the PCOS group showed that BMI and mFG
score were independently associated with scores of certain
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items. BMI appears to have significant effects on depressive
status and generalized anxiety disorder but not on the
remaining 4 subscales of SCARED. On the other hand,
mFG score was found to be associated only with panic
disorder. In agreement with the results of adult studies, our
findings showed that these manifestations seem to account
partially for the association between PCOS and emotional
distress in adolescent girls.
Some limitations exist in the current study. First, the
study was cross-sectional in design, which may not provide
definite information about cause-and-effect relationships.
For example, we were not able to assess prospectively
whether regression in PCOS or an improvement in the
BMI or mFG score leads to a subsequent improvement
in the anxiety and depressive states of the adolescent
girls with PCOS. Second, psychological parameters were
evaluated by self-rating scales; however, clinical interviews
are usually considered more precise than self-rated
questionnaires in determining the differences between
groups. Third, enrollment of patients and controls from
two sociodemographically distinct regions of Turkey
might have affected the results of the study.

Our findings demonstrate that patients with PCOS
exhibit higher levels of depression and certain types
of anxiety disorders including social and generalized
anxieties already in adolescence. These data suggest
that routine evaluation of adolescents affected by PCOS
should also entail assessment of mood disorders. Early
recognition and proper management of such comorbid
psychiatric illnesses in adolescents with PCOS would
promote psychological well-being, adherence to required
lifestyle changes, and medical treatment. Furthermore, the
presence of higher levels of depression and generalized
anxiety disorder in patients with higher BMI and the
presence of higher levels of panic disorder in patients with
higher mFG scores suggest, at least in part, an association
between severity of clinical symptoms of PCOS and degree
of anxiety and depression in adolescents with PCOS. In
this regard, clinicians should take into consideration
the effects of weight status and hirsutism on anxiety and
depressive states of adolescents with PCOS while designing
interventions to improve these mood disorders in young
patients with the condition.
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